Form D · Biotechnology

Minerva Neurosciences, Inc.

Burlington, MA · CIK 0001598646

Offering snapshot reported Jul 3, 2023 · SEC filing

Reported sold
$0
Offering amount: $20M
Investors reported
4
Form D · investor count
Minimum accepted
$0
Reported outside-investor minimum
First sale
Jun 30, 2023
As reported in this filing

What changed?

Latest filing versus its linked predecessor, where available.

No comparable changes in the displayed metrics.

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
Jul 3, 2023Initial$0No comparison4SEC filing
Mar 18, 2016Initial$1,000,000No comparison1SEC filing
Mar 24, 2015Initial$30,999,997No comparison22SEC filing

Offering details

Securities
Equity, Option to acquire, Security to be acquired
Exemptions
06b
Duration over one year
No
Business combination
No
Sales commissions
$0
Finders' fees
$0
Form D file number
021-485835

Source: Form D, filed Jul 3, 2023. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
Fred Ahlholm Executive
Frederick Ahlholm Executive
Marc Beer Director
Francesco De Rubertis Director
Hans Peter Hasler Director
Jeryl Hilleman Director
David Kupfer Director
Fouzia Laghrissi Thode Director
Mark Levine Executive
Remy Luthringer Director, Executive
Michele Ollier Director
Geoffrey Race Executive
Geoff Race Executive
Joseph Reilly Executive
Nico Vandervelpen Director
Jan Van Heek Director

Issuer details

Industry: Biotechnology (See others in industry)

Address:
1500 District Avenue
Burlington, MA, 01803